Biocept, Inc. Completes IPO

Represented Biocept, Inc. (Nasdaq:BIOC) in its $19 million initial public offering. The San Diego-based oncology diagnostics company offered 1.9 million shares of common stock for $10 each.

Biocept has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer.